SCHEMBL888100

SCHEMBL888100

CC(c1ccccc1[N+](=O)[O-])[C@]1(n2cnc3c(N)ncnc32)C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC28A1 O00337 2/20 0.42
ADORA3 P0DMS8 4/20 0.40
ADORA2A P29274 3/20 0.40
SLC29A1 Q99808 6/20 0.39
GMPS P49915 1/20 0.38
DPP4 P27487 1/20 0.38
MEN1 O00255 1/20 0.38
MAP3K7 O43318 1/20 0.38
SLC28A2 O43868 1/20 0.38
GAPDH P04406 1/20 0.38
MAPK1 P28482 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
STAT6 P42226 1/20 0.38
PI4KA P42356 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PI4K2B Q8TCG2 1/20 0.38
DOT1L Q8TEK3 1/20 0.38
PI4K2A Q9BTU6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL888082 0.97 SLC28A1 (0.40) SLC28A1ADORA3ADORA2ASLC29A1GMPS
SCHEMBL888231 0.89 SLC28A1 (0.40) SLC28A1ADORA3ADORA2ASLC29A1DPP4
Phosphoric Acid SCHEMBL888221 0.83 SLC28A1 (0.35) SLC28A1ADORA3ADORA2ASLC29A1DPP4
SCHEMBL887960 0.81 NNMT (0.34) SLC28A1ADORA3ADORA2ASLC29A1ADORA1
SCHEMBL888071 0.80 LMNA (0.37) SLC29A1
SCHEMBL888139 0.80 SLC29A1 (0.44) SLC28A1ADORA3ADORA2ASLC29A1GMPS
SCHEMBL1140763 0.79 SLC28A1 (0.46) SLC28A1ADORA3ADORA2ASLC29A1GMPS
Phosphoric Acid SCHEMBL888154 0.77 SLC29A1 (0.42) SLC28A1ADORA3ADORA2ASLC29A1GMPS
SCHEMBL13268742 0.76 SLC28A1 (0.44) SLC28A1ADORA3ADORA2ASLC29A1GMPS
Phosphoric Acid SCHEMBL1140775 0.74 SLC28A1 (0.40) SLC28A1ADORA3ADORA2ASLC29A1GMPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110287427-A1 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING LASERGEN, INC. (US) 2011-11-24 US disclosed
US-7964352-B2 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing LASERGEN, INC. (US) 2011-06-21 US disclosed
US-7897737-B2 Polymorphic identification; fluorescent dyes LASERGEN, INC. (US) 2011-03-01 US disclosed
US-20080132692-A1 Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing AGILENT TECHNOLOGIES, INC. 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132692-A1 Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing UNG, DCLRE1B, NT5C3B SLC28A1 467/4885ADORA3 113/4885ADORA2A 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.